MASSDEVICE ON CALL —Medtronic (NYSE:MDT) CEO Omar Ishrak this week unloaded 10,000 shares of company stock at an average price of about $53.58 apiece, a sale worth more than $535,000, according to SEC documents.
The per-share price is toward the higher end of the company’s 52-week average range, which has gone from $40.28 to $55.98.
The Minnesota medtech giant has been on something of a roll lately, gaining high marks from many Wall Street analysts. Deutsche Bank has a "hold" rating and a $56 price target on MDT shares, Barclay Capital recently raised their price target from $54 to $56 with an "equal weight" rating and Zacks has a "neutral" rating on the stock with a $55 price target, NorthForkvue.com reported.
The pros and cons of preventative mastectomy
Among women who opted to surgically remove a healthy breast out of fear of recurring breast cancer the vast majority say they’re glad they did it, despite the impact to their self-esteem, researchers said, but data suggests that patients may be far over-estimating the risk of recurrence and choosing prophylactic mastectomy based on unfounded fears.
Snake-like robot slithers up to ablate hard-to-reach brain tumors
University of Maryland researchers are developing a snake-like robotic ablation device that would partner with MRI systems to target and destroy tumors in hard-to-reach areas of the brain.
Smartphone diagnostics put check-ups in patients’ hands
German medical device researchers unveiled a smartphone-based diagnostics tool designed for consumers, able to detect blood glucose, lactate and cholesterol levels as well as other biomarkers.
Privacy under Obamacare – State health exchange employee leaks patient data
An employee of Minnesota’s state health insurance exchange accidentally leaked confidential data on more than 2,400 patients to an unauthorized insurance broker, prompting concern from House Republicans raising eyebrows about the treatment of private information under the new healthcare structure.